Analysts See $-0.43 EPS for GTx, Inc. (GTXI)

July 14, 2018 - By Jason Grubb

GTx, Inc. (NASDAQ:GTXI) Logo

Analysts expect GTx, Inc. (NASDAQ:GTXI) to report $-0.43 EPS on August, 13.They anticipate $0.03 EPS change or 7.50 % from last quarter’s $-0.4 EPS. After having $-0.62 EPS previously, GTx, Inc.’s analysts see -30.65 % EPS growth. The stock decreased 1.91% or $0.29 during the last trading session, reaching $14.92. About 46,124 shares traded. GTx, Inc. (NASDAQ:GTXI) has risen 489.32% since July 14, 2017 and is uptrending. It has outperformed by 476.75% the S&P500.

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions. The company has market cap of $358.55 million. It focuses on the development of selective androgen receptor modulators for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC). It currently has negative earnings. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with advanced androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI.

Another recent and important GTx, Inc. (NASDAQ:GTXI) news was published by which published an article titled: “GTx Added to the Russell 3000® Index” on June 25, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: